N/A N=1,157 Safety and Efficacy of Daily Use of Micamlo® Combination Tablets AP in Patients With Hypertension
Hypertension
Primary: Incidence of Drug-related Adverse Events — 60 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=806 The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome
Deep Venous Thrombosis
Primary: Incidence of Post-thrombotic Syndrome (PTS) — 44; 37 participants — p=.58
Phase 2 N=37 BIBF 1120 for Recurrent High-Grade Gliomas
Glioblastoma · Gliosarcoma · Anaplastic Astrocytoma
Primary: 6-Month Progression Free Survival — 0 percentage of participants
Phase 4 N=25 Single Dose Bronchodilatory Study in Asthma
Asthma
Primary: Change From Baseline in FEV1 — 2.84 Liter
Phase 2 N=23 Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)
Diabetes Mellitus, Type 2
Primary: Postprandial Glucose (PPG) Excursion Following a Liquid Meal — 162.71; 144.67; 169.38; 166.05 Milligrams per deciliter (mg/dL) — p=0.0034
N/A N=30 Analysis of Snore Sound Following Minimal Invasive Surgery in Sleep-disordered Breathing Patients
Primary Snoring · Obstructive Sleep Apnea
Primary: Change in VAS Score After MIS — -1.4; -3.3 units on a scale — p=<0.05
Phase 4 N=13 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients
Allergic Conjunctivitis
Primary: Patient-Assessed Ocular Itching — 2.2; 2.2; 0.5; 0.5 units on a scale
Phase 3 N=238 The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)
Chronic Hepatitis C Genotype 1
Primary: Percentage of Participants Achieving Sustained Virologic Response At Follow-up Week 24 (SVR24) Among Participants Who Received At Least One Dose of Any Trial Medication…
N/A N=29 Pharmacogenetics of Warfarin Induction and Inhibition
Healthy
Primary: Warfarin Clearance. — 282; 246; 180; 84 mL/h — p=<0.0001
Phase 2 N=171 Green Tea and Tai Chi for Bone Health
Osteoporosis
Primary: Change From Baseline (100%) in Ratio of Bone Formation Marker to Bone Resorption Marker — 106.1; 103.6; 112.3; 113.0 percentage change from baseline
Phase 3 N=168 Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI
Gastroesophageal Reflux Disease
Primary: Daytime Heartburn, Number of Days in Week Symptoms Intensity Score < 3 (Better) — 6.6; 5.9; 6.1 days — p=0.04
Phase 2 N=22 Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Primary: Complete Response Rate — 36 percentage of patients
N/A N=22 Impact of Vitamin D Supplementation on Lactation Associated Bone Loss
Osteoporosis
Primary: Change in Bone Mineral Density (BMD) in HIP at 6 Months — -0.041; 0.011 grams/cm^2
Phase 3 N=8,381 ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
Neoplasms, Breast
Primary: Disease-Free Survival (DFS) at the Primary Analysis — 1.9; 1.3; 1.0; 1.5 Years — p=0.048
N/A N=168 Initiating Contraception After Emergency Contraception From Pharmacy
Contraceptive Use After Emergency Contraception
Primary: Self-reported Uptake of Effective Ongoing Contraception (Not Condoms) — 5; 13; 22; 0 participants — p=<0.001